<DOC>
	<DOCNO>NCT00019825</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness decitabine treat patient unresectable lung esophageal cancer malignant mesothelioma pleura .</brief_summary>
	<brief_title>Decitabine Treating Patients With Unresectable Lung Esophageal Cancer Malignant Mesothelioma Pleura</brief_title>
	<detailed_description>OBJECTIVES : - Determine pharmacokinetics , toxicity , maximum tolerate dose decitabine patient unresectable primary small cell non-small cell lung cancer , unresectable esophageal cancer , malignant pleural mesothelioma . - Measure expression NY-ESO-1 tissue sample patient receive drug . - Assess serologic response NY-ESO-1 patient receive drug . - Measure expression p16 tumor suppressor gene patient receive drug . OUTLINE : This dose-escalation study stratification group . Patients stratify accord number prior therapy ( 2 few v 3 ) . Patients receive decitabine IV continuously day 1-3 . Treatment repeat every 5 week 2 course absence disease progression unacceptable toxicity . Patients stable respond disease completion second course receive 2 additional course . Cohorts 3-6 patient receive escalate dos decitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Once MTD determine particular stratum , additional patient stratum treat MTD . Patients follow 1 month . PROJECTED ACCRUAL : A maximum 72 patient ( 36 per stratum ) accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm unresectable primary small cell lung cancer ( SCLC ) nonsmall cell lung cancer ( NSCLC ) , unresectable esophageal cancer , malignant pleural mesothelioma , pleural effusion secondary extrathoracic malignancy Disease must readily accessible biopsy endoscopy percutaneous fineneedle aspiration Extrathoracic metastatic disease allow evidence active intracranial leptomeningeal metastases Patients treat prior resection radiotherapy intracranial metastatic disease may eligible provided evidence active disease two MRIs ( take one month apart ) patient require anticonvulsant medication steroid control residual symptom No limited stage SCLC operable NSCLC PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 6 month Hematopoietic : Platelet count great 100,000/mm^3 Hemoglobin great 10 g/dL WBC great 3,500/mm^3 Hepatic : PT normal Bilirubin le 1.5 time upper limit normal Renal : Creatinine great 1.6 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : Any following condition require clearance cardiologist : Prior coronary artery disease Prior transmural myocardial infarction Congestive heart failure Fixed defect thallium scan ejection fraction great 40 % No unstable angina No recent deep venous thrombosis require anticoagulation Pulmonary : FEV1 DLCO great 30 % predict pCO_2 le 50 mm Hg pO_2 great 60 mm Hg room air No recent pulmonary embolism require anticoagulation Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active infection HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : At least 30 day since prior biologic therapy malignant tumor Chemotherapy : No prior decitabine At least 30 day since prior chemotherapy malignant tumor Endocrine therapy : See Disease Characteristics Radiotherapy : See Disease Characteristics At least 30 day since prior radiotherapy malignant tumor ( 14 day localize radiotherapy nontarget lesion ) recover Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2004</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>advanced malignant mesothelioma</keyword>
	<keyword>recurrent malignant mesothelioma</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>malignant pleural effusion</keyword>
</DOC>